Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
GE Healthcare to open biotechnology manufacturing centre in UK
Located at the Stevenage Bioscience Catalyst, the facility includes 280sqm of cleanroom space
Research & Development
Consortium of UK Universities and global pharma companies launch £40m innovation fund
Apollo Therapeutics Fund will support translation of academic science into medicines for a broad range of diseases
Research & Development
Ian Tomlinson becomes Independent Chairman of Stevenage Bioscience Catalyst Board
Will guide open innovation campus in a phase of rapid development
Research & Development
Stevenage Bioscience Catalyst to fund six projects to fight neurodegenerative disease
Diverse players collaborate on first step in plan to tackle disorder through open innovation
Research & Development
New £55m cell therapy manufacturing centre to be built in Stevenage, UK
Will open in 2017 and create up to 150 jobs
Research & Development
GE Healthcare Life Sciences links up with Stevenage Bioscience Catalyst (SBC)
Joins neurodegenerative disease challenge and expands commitment to open innovation in healthcare
Research & Development
Stevenage Bioscience Catalyst gains £3m in funding
One tenant has also secured further funding, while another has extended its research collaborations
Subscribe now